中国医疗改革_谁能生存_（英文版）_26页_5mb

报告摘要

Summary of China's Healthcare Reforms: Who Will Survive?

Core Content

China's healthcare market is projected to grow rapidly, with total healthcare expenditure expected to surpass USD 1 trillion by 2020, growing at a CAGR of over 19%. The country's aging population, which is expected to increase the old age dependency ratio to 43% by 2045, will significantly raise healthcare costs and put pressure on government budgets. Currently, China spends just over 5% of its GDP on healthcare, but this is expected to rise.

Main Goals of Reforms

The primary goals of the healthcare reforms launched in 2015 are to:

Enhance the quality, coverage, and sustainability of the healthcare system.
Reduce costs by creating a more cost-efficient, decentralized system.
Encourage the development of general practitioners (GPs) and private healthcare facilities.
Promote a hierarchical system where patients must first visit lower-level providers before accessing level 3 hospitals.

Key Reforms and Their Impacts

Reform	Date	Issuing Department	Document	Affected Industries	Highlights
Longer clinical trials	Nov 2015	General Office of the State Council	Forwarding of Opinions on Further Encouraging and Guiding the Establishment of Medical Institutions by Social Capital	Pharmaceuticals, Medical Devices	Standardized clinical trial process for all drugs
Industry Controlled Correspondence Report (generic drugs)	Feb 2016	General Office of the State Council	Opinions on carrying out quality and efficacy consistency evaluation for generic drugs	Pharmaceuticals	Generic drug companies must go through costly ICC approval process
"Two Invoice" Policy	Apr 2016	General Office of the State Council	Notice on key tasks of deepening the medical and health system reform in 2016	Pharmaceuticals, Medical Devices	Only two invoices allowed for sales, reducing mark-ups
Government price pressure	Nov 2015	NHFPC	Opinions on controlling unreasonably medical expenses in public hospitals	Pharmaceuticals, Medical Devices	Bidding prices reduced by up to 30%
Encouragement of local companies and products	Aug 2015	General Office of the State Council	Opinions on reforming the review and approval system for drugs and medical devices	Medical Devices	Informal privileges for local firms
Tiered medical service system	Sep 2015	General Office of the State Council	Guiding opinions on propelling the building of a hierarchical diagnosis and treatment system	Medical Devices, Healthcare Service Providers	Patients must first visit lower-level providers
Encouragement of private health insurance and private hospitals	Jun 2015	General Office of the State Council	Notice on policies and measures for promoting the accelerated development of private medical institutions	Healthcare Service Providers	Relaxing restrictions on foreign-owned hospitals
Doctor multi-site licensed	Apr 2016	General Office of the State Council	Notice on key tasks of deepening the medical and health system reform in 2016	Healthcare Service Providers	Doctors can work in multiple institutions
Implementation of DGR system	Nov 2015	NHFPC	Opinions on controlling unreasonably medical expenses in public hospitals	Pharmaceuticals, Medical Devices, Healthcare Service Providers	Reimbursement based on disease groups, not services

Challenges and Opportunities

Pharmaceuticals

Challenges:

Price cuts and two fapiao invoicing system will reduce profit margins.
Smaller distributors and local generic competitors will gain more influence.
Increased transparency in pricing for patented drugs may affect MNCs.

Opportunities:

Innovative Products: Unique and innovative drugs will continue to command higher prices.
Niche Markets: Focusing on specific provinces and products can help MNCs remain competitive.
Diversification: Combining pharmaceuticals with other healthcare areas like medical devices and telemedicine can provide synergies.
M&A: Acquiring local firms can help MNCs navigate the regulatory environment and secure market share.

Medical Devices

Challenges:

Two fapiao invoicing system may increase operational complexity.
Government support for local companies may limit market access for MNCs.
Price pressure and the need for local innovation may reduce the number of new products introduced.

Opportunities:

Multiple Brands/Product Lines: Offering different products for various customer segments can increase market reach.
M&A: Acquiring local firms can provide cost and registration advantages.
Overlooked Markets: Patient-pay devices and small but profitable markets have less local competition.
Innovative Products: High-tech and unique devices will still be in demand.

Healthcare Service Providers

Challenges:

Public perception favors large level 3 hospitals over GPs and private facilities.
Stigma and lack of trust in private and GP services may hinder adoption.

Opportunities:

Decentralized System: A shift to a hierarchical system will increase demand for GPs and lower-level hospitals.
Private Facilities: Development of private healthcare services will create new opportunities for service providers.
Private Insurance: Growth in private insurance will support the expansion of private healthcare facilities and services.

Conclusion

China's healthcare reforms are driven by demographic changes and the need for cost efficiency. While the reforms pose challenges for multinational companies, particularly in the pharmaceutical and medical device sectors, they also offer opportunities for those that can innovate, diversify, and adapt to the new regulatory and market landscape. The future of the Chinese healthcare system is expected to be more decentralized, with a greater role for private healthcare and GPs, creating a more sustainable and efficient model. Companies that can navigate these changes and leverage the opportunities will likely thrive in this evolving market.

展开完整摘要